Serum ischemia-modified albumin levels at diagnosis and during treatment of late-onset neonatal sepsis

Basit Öğe Kaydı
dc.contributor.authorYerlikaya, F. Humeyra
dc.contributor.authorKurban, Sevil
dc.contributor.authorMehmetoglu, Idris
dc.contributor.authorAnnagur, Ali
dc.contributor.authorAltunhan, Huseyin
dc.contributor.authorErbay, Ekrem
dc.contributor.authorOrs, Rahmi
dc.date.accessioned2024-02-23T14:34:39Z
dc.date.available2024-02-23T14:34:39Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractSepsis is one of the most common infectious conditions in the neonatal period, and continues as a major source of morbidity and mortality. The aim of this study is to determine serum ischemia-modified albumin (IMA) levels in late-onset neonatal sepsis at the time of diagnosis and after therapy, and to show the meaningful on the follow-up. Also, it is aimed to compare serum IMA levels with serum C-reactive protein (CRP), procalcitonin (PCT) levels and white blood cell count. The study was performed on 33 premature babies with sepsis and 21 healthy premature controls at 7-28 days of age. In the sepsis group, biochemical parameters and blood culture samples were obtained from the blood at the onset and on the fifth day of treatment for each patient. Serum IMA, CRP, PCT and white blood cell count were significantly higher in the sepsis group before treatment when compared with the control group. In addition, the levels of IMA were positively correlated with white blood cell count, CRP and PCT in the sepsis group before treatment. In conclusion, serum IMA levels may be useful in late-onset neonatal sepsis at the time of diagnosis and after therapy. As far as we know this is the first report about the assesment of illness diagnosis and after therapy using serum IMA levels, and further studies are needed to confirm our results in larger groups of patients.en_US
dc.identifier.doi10.3109/14767058.2013.876621
dc.identifier.endpage1727en_US
dc.identifier.issn1476-7058
dc.identifier.issn1476-4954
dc.identifier.issue17en_US
dc.identifier.pmid24345053en_US
dc.identifier.scopus2-s2.0-84911924315en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1723en_US
dc.identifier.urihttps://doi.org/10.3109/14767058.2013.876621
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15686
dc.identifier.volume27en_US
dc.identifier.wosWOS:000344080600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Maternal-Fetal & Neonatal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectC-Reactive Proteinen_US
dc.subjectIschemia-Modified Albuminen_US
dc.subjectLate-Onset Neonatal Sepsisen_US
dc.subjectProcalcitoninen_US
dc.subjectWhite Blood Cell Counten_US
dc.titleSerum ischemia-modified albumin levels at diagnosis and during treatment of late-onset neonatal sepsisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu